ArticleMolecular biology reports2026
Study of CD36 receptor gene expression in obese and non-obese chronic kidney disease patients.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is a global health challenge accelerated by obesity. This study evaluated the association of peripheral Cluster of Differentiation 36 (CD36) mRNA expression and serum soluble CD36 (sCD36) with CKD, investigating how obesity modulates these markers.
methodsSeventy-five participants were stratified into controls (n = 25), non-obese CKD (n = 25), and obese CKD patients (n = 25). Markers were quantified via RT-qPCR and ELISA.
resultsBoth CD36 mRNA and serum sCD36 significantly increased in CKD, peaking in the obese CKD group (p < 0.001). While strongly correlated across the whole cohort (r = 0.69, P < 0.001), stratified analysis revealed divergent behaviors. CD36 mRNA lost lipid associations but selectively correlated with serum urea exclusively in the obese CKD subgroup (r = 0.42, P = 0.04). Conversely, serum sCD36 maintained robust, obesity-independent correlations with pro-atherogenic lipids (triglycerides, total cholesterol, Low-Density Lipoprotein (LDL); P < 0.001) and an inverse correlation with High-Density Lipoprotein (HDL) in both CKD cohorts, losing renal associations. ROC analysis demonstrated superior diagnostic performance for serum sCD36 (Area Under the Curve (AUC) = 0.94, sensitivity 98%, specificity 84% at 0.64 ng/mL) over mRNA expression (AUC = 0.87, sensitivity 82%, specificity 88%) in discriminating CKD from controls.
conclusionCD36 transcriptional and translational tiers exhibit distinct dynamics in CKD. Peripheral mRNA reflects localized uremic stress under obese conditions, whereas circulating sCD36 serves as a stable, obesity-independent indicator of systemic lipotoxicity and a potential diagnostic or associative biomarker.
Indexed as
Identifiers
42377608What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.